Vir Biotechnology (VIR) closed at $9.96 on October 16, 2026, down 4.9% from the previous close, on volume of 1,634,838 shares (30-day average 2,061,038).
Data as of October 16, 2026.
16-Oct-2026
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Wed, 14-Oct 11:40 AM ET)
Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugs
Seeking Alpha News (Wed, 14-Oct 9:09 AM ET)
Vir Biotechnology seals major oncology alliance with Gilead
TipRanks (Wed, 14-Oct 8:59 AM ET)
Business Wire (Wed, 14-Oct 8:30 AM ET)
Market Chameleon (Thu, 8-Oct 5:34 AM ET)
Business Wire (Thu, 8-Oct 8:30 AM ET)
Vir Biotechnology Appoints David Liu as Chief Medical Officer
Business Wire (Wed, 7-Oct 8:30 AM ET)
Business Wire (Mon, 5-Oct 4:05 PM ET)
Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer
Business Wire (Thu, 1-Oct 8:30 AM ET)
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire (Mon, 31-Aug 4:05 PM ET)
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Vir Biotechnology trades on the NASDAQ stock market under the symbol VIR.
As of October 16, 2026, VIR stock price declined to $9.96 with 1,634,838 million shares trading.
VIR has a beta of 1.41, meaning it tends to be more sensitive to market movements. VIR has a correlation of 0.10 to the broad based SPY ETF.
VIR has a market cap of $1.61 billion. This is considered a Small Cap stock.
Last quarter Vir Biotechnology reported $239 million in Revenue and $.47 earnings per share. This beat revenue expectation by $9 million and missed earnings estimates by -$.41.
In the last 3 years, VIR traded as high as $14.45 and as low as $4.16.
The top ETF exchange traded funds that VIR belongs to (by Net Assets): IJR, VTI, VB, IWM, XBI.
VIR has outperformed the market in the last year with a return of +71.7%, while the SPY ETF gained +16.7%. In the last 3 month period, VIR beat the market returning +6.0%, while SPY returned +1.9%. However, in the most recent 2 weeks VIR has underperformed the stock market by returning -10.8%, while SPY returned -0.8%.
VIR support price is $10.08 and resistance is $10.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VIR shares will trade within this expected range on the day.
